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We investigated factors affecting analgesic oxycodone concentrations after breast cancer 
surgery in 1,000 women. Preoperatively, we studied heat and cold pain sensitivities and 
anxiety scores. Postoperatively, rest and motion pain intensities were measured and 
intravenous oxycodone was administered until satisfactory analgesia. At this point, the 
mean oxycodone concentration (variation coefficient) was 33.3 ng/ml (66%), and it was 21.7 
ng/ml (69%) when the patient requested oxycodone again. At both time points, the 
concentrations varied >100-fold between individuals. The analgesic oxycodone 
concentration was increased by 21.3% per motion pain intensity score on a 0-10 scale and 
by 22.3% if axillary clearance was performed instead of sentinel node biopsy (P<0.001). 47 
women, older and less anxious than others (P<0.01), required no oxycodone. Anxiety, age, 
chronic pain or preoperative pain sensitivity were not independently associated with the 
analgesic oxycodone concentration. CYP2D6 and CYP3A genotypes did not affect analgesic 





Parenteral oxycodone is increasingly used worldwide. However, pharmacokinetic data of 
intravenous oxycodone in the management of postoperative pain are limited.1 The dose of 
oxycodone needed for satisfactory analgesia varies remarkably between individuals. 2 
 
Several factors can affect the need of oxycodone. Different types of surgery predispose 
patients to variable postoperative pain intensities depending on the tissue being operated 
and invasiveness of surgery.3,4 Moreover, high levels of anxiety associate with increased 
pain sensitivity and opioid requirement.4-6 Older age increases plasma oxycodone 
concentrations and lowers its dose requirement.7,8  This may be due to lower percentage of 
body water and to decreased liver and kidney function.8,9  In addition, chronic nicotine 
exposure may increase postoperative pain intensity and opioid consumption, possibly due 
to adaptive changes in the endogenous opioid system.10-12 Abstinent tobacco-smokers also 
require higher opioid doses postoperatively.13  
 
Oxycodone is metabolized by the cytochrome P450 (CYP) enzymes CYP3A4/5 and 2D6 
(Figure 1). The major pathway is N-demethylation by CYP3A4 to noroxycodone, which lacks 
opioid activity.14 Metabolism via CYP2D6 yields oxymorphone, which has a strong opioid 
potency,14 but its concentration remains very low.15 Further oxidation of both noroxycodone 
and oxymorphone results in noroxymorphone, which is a strong µ-opioid receptor agonist, 
but does not penetrate the blood brain barrier and consequently has only peripheral 
effects.16 Ketone reduction yields two stereoisomers of oxycodol  from oxycodone, 
noroxycodol from noroxycodone, and oxymorphol from oxymorphone.15 Oxycodone and its 
metabolites are excreted via kidneys, in unconjugated and conjugated forms.15,17 Inhibition 
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and induction of CYP3A4 have had marked effects on plasma concentration of 
oxycodone,18,19 but inhibition of CYP2D6 or genetically poor CYP2D6 metabolism have only 
marginally increased oxycodone concentrations.20,21 In experimental pain models in healthy 
volunteers, CYP2D6 poor metabolizers (PM) experienced less pain relief with oxycodone 
than extensive metabolizers (EM).22 However, the same research group did not find any 
difference in the post-operative analgesic effect of oxycodone between these two CYP2D6 
phenotypes.21 
 
Variability in genes related to pharmacodynamics may also affect the efficacy of 
oxycodone.23,24 For example, the OPRM1 c.118A>G (rs1799971, p.Asn40Asp) single 
nucleotide variation (SNV) has been found to affect postoperative oxycodone consumption, 
but no studies have explored its effect on the required analgesic concentrations of 
oxycodone.  
 
The analgesic oxycodone concentrations have been studied only in small samples (≤ 50 
individuals) after abdominal surgery.25-27 Our aim was to characterize analgesic plasma 
concentrations of oxycodone in 1000 women after breast cancer surgery, to find out how 
much they vary between individuals, and what factors explain this variation. This 
information could be valuable for the individualized management of postoperative pain and 
for future pharmacogenetic studies of analgesics.  
 
We examined 1,000 Finnish women undergoing surgery for breast cancer. In the post-
operative phase, plasma oxycodone and its main metabolite concentrations were measured 
when the patients considered their analgesia satisfactory for the first time by intravenous 
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dose titration and when they requested a new dose of oxycodone. Various patient- and 
surgery-related factors as well as factors related to the pharmacology of oxycodone were 







Oxycodone concentrations at the two time points 
Plasma concentrations of oxycodone and its metabolites at the first state of satisfactory 
analgesia were available from 938 out of the 1,000 patients. 399 patients did not require 
further oxycodone after having achieved satisfactory analgesia in the post-anesthesia care 
unit (PACU); therefore the concentrations were available from 539 patients at the latter 
time point. Their analgesic oxycodone concentrations did not differ significantly from those 
of the 399 patients who did not need a new dose of oxycodone after having achieved 
satisfactory analgesia. The patients who did not request more oxycodone were older (mean 
58.8 vs. 55.3 years, P < 0.001) and had preoperatively less anxiety (P < 0.001) than the 539 
patients who requested a new dose after satisfactory analgesia (Supplementary Table 1). 47 
patients did not request any oxycodone in the PACU. They were significantly older (P < 
0.01), shorter (P < 0.01), and had significantly less preoperative anxiety (P < 0.01) than the 
other patients (Supplementary Table 2). As they were not given oxycodone, their data could 
not be used in other analyses. Furthermore, the concentration data at the first state of 
satisfactory analgesia were missing from 15 patients.  
 
Oxycodone plasma concentrations needed for satisfactory analgesia varied greatly between 
individuals (range <0.1-311 ng/ml). The variation remained high (range <0.1-191 ng/ml) at 
the time point when the patient requested a new dose, i.e., on the average 162 min later. 
The plasma concentrations of both oxycodone and its metabolites correlated strongly 




Geometric means and geometric CV%s (coefficient of variation) for oxycodone and 
metabolite plasma concentrations at the first state of satisfactory analgesia were: 
oxycodone 33.3 ng/ml (66%), noroxycodone 1.46 ng/ml (106%), oxymorphone 0.11 ng/ml 
(110%) and noroxymorphone 0.26 ng/ml (150%). When the patient requested a new dose, 
the concentrations were: oxycodone 21.7 ng/ml (69%), noroxycodone 3.67 ng/ml (73%), 
oxymorphone 0.14 ng/ml (89%), and noroxymorphone 0.67 ng/ml (92%). 
 
The analgesic plasma concentrations of oxycodone correlated significantly with the weight-
adjusted total dose of oxycodone needed for the first state of adequate analgesia (Figure 3). 
Yet, the individual concentrations varied up to 4-fold after the same weight-adjusted total 
dose. The individual with the highest oxycodone concentration at both time points also had 
an exceptionally low dose/concentration ratio. We could not identify any obvious reason for 
these exceptionally high concentrations. Excluding her from the statistical analysis did not 
change the conclusions. 
 
Factors affecting analgesic oxycodone concentrations 
In a multivariate linear regression analysis, pain intensity after surgery and the type of 
surgery strongly associated with the analgesic oxycodone concentration. The analgesic 
oxycodone concentration increased by 21.7% (95% CI 17.5-26.1, P< 0.001) per one motion 
pain intensity score increase on a 0-10 Numerical Rating Scale (NRS) (Table 1). The 170 
patients with high motion pain intensity scores (NRS 7-10) needed nearly two-fold higher 
plasma oxycodone concentrations (geometric mean 50.7 ng/ml) than the 699 patients 
having moderate pain intensity (NRS 4-6; oxycodone 31.6 ng/ml), and almost three-fold 
higher concentrations than the 59 patients with low postoperative motion pain intensity 
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(NRS 0-3; oxycodone 17.8 ng/ml) (Figure 4). The mean intravenous oxycodone doses needed 
for the analgesic concentrations in these three pain score groups were 0.18 mg/kg, 0.10 
mg/kg, and 0.07 mg/kg, respectively (Table 2). The motion and rest pain intensities were in 
almost complete correlation (r=0.99) (Table 1.). 
 
The plasma oxycodone concentration required for satisfactory analgesia was significantly 
higher (mean 23.4%, 95% CI 12.1-36.0%, P <0.001) in those who had removal of the axillar 
lymph nodes (axillary clearance, AC) compared with sentinel node biopsy only. In patients 
having undergone axillary clearance, the geometric mean plasma oxycodone concentration 
was 38.7 ng/ml (66%) and in those having undergone sentinel node biopsy it was 29.6 ng/ml 
(62%). The corresponding doses of oxycodone needed for these analgesic concentrations 
were 0.13 mg/kg and 0.10 mg/kg, respectively. The type of breast surgery (breast 
conserving surgery/mastectomy) had no statistically significant effect on the analgesic 
oxycodone concentration (Table 1.). Also other patient characteristics (e.g., age, smoking or 
body mass index, preoperative anxiety, heat pain or cold pain sensitivity) showed no 
statistically significant effect on the analgesic plasma concentrations of oxycodone.  
 
CYP2D6, CYP3A4/5 and OPRM1 genotypes  
The CYP2D6 metabolizer status could be inferred from the genotype in 918 patients. There 
were 80 ultra-rapid metabolizers (UM), 799 extensive metabolizers (EM), 16 intermediate 
metabolizers (IM), and 23 poor metabolizers (PM). The genotype groups did not differ in 
regard to the demographic factors. Major differences were seen between the CYP2D6 
genotype groups in the oxymorphone and noroxymorphone concentrations, both when the 
patients reported satisfactory analgesia for the first time and when they needed a new dose 
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(Table 3). No significant differences were seen in the oxycodone or noroxycodone 
concentrations between the CYP2D6 genotypes. CYP3A4 rs35599367 (*22 allele) or CYP3A5 
rs776746 (*3 allele) SNVs showed no significant effects on oxycodone or its metabolite 
concentrations at either of the two time points. Neither the CYP2D6 nor the CYP3A4/5 
polymorphisms affected the duration of the analgesic effect, i.e., the time between 
satisfactory analgesia and the need for a new oxycodone dose. The OPRM1 c.118A>G 







To our knowledge, this is the largest study assessing analgesic oxycodone concentrations 
and factors affecting these in the immediate postoperative phase. The patient group was 
homogenous as it consisted of only female patients sharing the same ethnic background 
(Caucasians). The study showed that there is wide variation in the analgesic plasma 
concentrations of oxycodone after breast cancer surgery. The concentration ranged from 0, 
i.e., no oxycodone needed, to 311 ng/ml. Postoperative pain intensity and type of axillary 
surgery were the most important factors associating with the analgesic oxycodone 
concentration. Axillary surgery was associated with significantly more pain than sentinel 
biopsy. However, even in the axillary surgery group, some patients did not need any 
oxycodone in the PACU whereas some patients required high plasma oxycodone 
concentrations in the absence of axillary surgery.  
 
Type of surgery 
The type of surgery that is performed to operate breast cancer depends mainly on the 
cancer status. The patients may need either removal of the breast (mastectomy) or 
resection of part of it. In addition, sentinel biopsies are performed to confirm the presence 
or absence of metastasis in the axillary lymph nodes.  Axillary clearance is related to a high 
risk of nerve injury, which has been reported to associate with more intense postoperative 
pain. In accordance with this, axillary clearance significantly increased plasma oxycodone 
concentrations needed for satisfactory analgesia compared with sentinel node biopsy. 
Evoked postoperative pain is usually more severe than pain at rest. We tested evoked pain 
by asking the patient to raise the arm ipsilateral to surgery. Even though pain on movement 
showed the most significant association with analgesic plasma oxycodone concentrations, 
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also pain at rest was a good predictor. As the rest pain was in strong correlation with pain 
during movement, it was not entered into the linear regression model. When considering 
the association between type of surgery and analgesic oxycodone concentrations, it can be 
expected that even higher concentrations than those reported in the current study may be 
needed after more extensive surgery. In line with this, two recent studies of 50 patients 
each suggested that the average analgesic concentration after open abdominal surgery 
would be about 75 ng/ml.27 Three small studies (N=22-23) have assessed the minimum 
effective analgesic plasma oxycodone concentrations after laparoscopic cholecystectomies. 
One reported that the mean analgesic plasma concentration is 45 or 50 ng/ml.25 The second 
study suggested that depending on whether 1 g or 2 g of intravenous acetaminophen was 
co-administered, the analgesic plasma concentration of oxycodone would be 62 ng/ml or 70 
ng/ml, respectively.26 The third study reported that the average analgesic concentration of 
oxycodone was 98 ng/ml or 80 ng/ml depending on whether 10 mg or 50 mg of intravenous 
dexketoprofen was co-administered, respectively.28 The preoperative analgesic in our study 
was 1 g acetaminophen orally. 
  
Pain sensitivity and anxiety  
Anxiety associates with pain sensitivity and fear of pain.6,29 Anxious patients expect to 
experience more pain and also report higher pain intensity in experimental pain tests, and in 
acute and chronic pain. In the current study, anxiety was not independently associated with 
postoperative analgesic oxycodone concentrations in the multivariate linear regression 
analysis. This may be partly due to the fact that our patients had, on average, relatively low 
levels of anxiety. It is also possible that the effects of anxiety on analgesic oxycodone 
concentration were conveyed through pain intensity scores in the regression analysis. 
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Patients who did not need any oxycodone, or did not need further oxycodone in the PACU 
after having achieved satisfactory analgesia, had significantly less anxiety than patients who 
needed additional oxycodone.   
 
Age  
In the linear regression analysis, age was not significantly associated with the analgesic 
oxycodone concentration. However, patients who did not need any oxycodone were 
significantly older than those who did. This agrees with the reports that older patients have 
less postoperative pain.30 Similarly, those patients, who did not need further oxycodone in 
the PACU after having achieved satisfactory analgesia, were significantly older than those 
who did. Previously Kaiko et al.31 have reported higher age to be associated with increased 
sensitivity to oral oxycodone. The need of lower total doses of oxycodone by elderly 
patients has been related to a prolonged elimination of oxycodone.7  
 
Gender, OPRM1, and smoking  
All our patients were women. The results can therefore not be generalized to male patients. 
Kaiko et al.31 also reported that women are more sensitive to the effects of oral oxycodone 
than men. We have previously reported in this patient cohort that the OPRM1 c.118A>G 
polymorphism explained only 1% of the variance in the oxycodone dose needed for 
satisfactory analgesia. Only 35 patients were homozygous for the minor allele (GG) and on 
average they needed 30% more oxycodone for satisfactory analgesia.24 However, in the 
current analysis the OPRM1 c.118A>G polymorphism had no significant effect on the 
analgesic oxycodone concentration. Nicotine has analgesic effects and abstinent smokers 
request more opioids in the postoperative period than non-smokers.13 In the current study, 
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however, tobacco smoking did not have a significant impact on analgesic oxycodone 
concentrations. This may be explained by the fact that less than 20% of the women smoked, 
and smoking was mostly occasional. 
 
Pharmacokinetic factors  
Our study was designed to focus on the analgesic oxycodone concentrations after initial 
titration to adequate pain relief attempting to minimize interference by pharmacokinetic 
factors. The brain and plasma concentrations of oxycodone have been reported to achieve 
equilibrium relatively fast, compared with morphine. The average transfer half-life from 
plasma to brain is 11 min for oxycodone,32 whereas it can vary from 1.6 to 4.8 hours for 
morphine.33 This difference may be due to an active transport of oxycodone through the 
blood-brain barrier into the brain.34,35   Preclinical studies suggest that the free brain 
concentrations of oxycodone could be clearly higher than those in plasma.36 This would 
suggest that the brain oxycodone concentrations are not directly commensurate to plasma 
concentrations, and that differences in the still unidentified transport protein could explain 
some of the variation in the analgesic plasma concentrations of oxycodone.   
 
CYP2D6 genotype did not affect the analgesic oxycodone concentrations, but it was 
associated with metabolite formation. As expected, the concentrations of oxymorphone in 
the PM and IM patients were about one third compared with the UM patients. The effect of 
CYP2D6 genotype was also evident in the plasma noroxymorphone concentrations, 
particularly in the second plasma samples, where the UM patients had nearly 10-fold higher 
noroxymorphone concentrations than the PM-patients. The high (7.6%) frequency of the 
UM variants among the breast cancer patients corresponds well with the UM frequency of 
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7.2% in healthy Finnish subjects.37 The CYP2D6 status did not affect the time the patients 
remained satisfied with analgesia, which would indicate lack of significant analgesic 
contribution by the metabolites. This is also supported by the fact that when the patients 
requested a further dose of oxycodone, the oxycodone concentrations had decreased to an 
average of 21.7 ng/ml from the 33.3 ng/ml at the first state of satisfactory analgesia, 
whereas the concentrations of the metabolites had risen. CYP3A4*22 and CYP3A5*3 alleles 
did not show any significant effect on oxycodone or metabolite concentrations, possibly due 
to small effects or the low number of minor allele carriers. 
 
What does analysing analgesic oxycodone concentrations add to monitoring oxycodone 
requirements? 
As measurement of central nervous system (CNS) oxycodone concentrations is rarely 
feasible, plasma oxycodone concentrations should be the most sensitive measure to assess 
the individual relationship between oxycodone and its analgesic effect. Fast development of 
equilibrium between CNS and plasma concentrations of oxycodone enables rapid titration 
to the analgesic effect and minimal interference by other pharmacokinetic factors. Thus, 
several factors of interest relating to the pharmacogenetics and the transporter systems 
relevant to oxycodone may be studied using analgesic oxycodone concentrations as a 
“phenotype”.  
 
To conclude, postoperative analgesic plasma oxycodone concentrations varied more than a 
100-fold between individuals. The major factors predicting the analgesic oxycodone 
concentrations were immediate postoperative pain intensity and whether the patient had 
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undergone axillary clearance or not. Estimation of immediate postoperative pain intensity is 





Our study population consisted of 1,000 Finnish women diagnosed with non-metastasized 
breast cancer who were to undergo surgery for breast cancer at the Breast Surgery Unit, 
Helsinki University Hospital, Helsinki, Finland, between August 2006 and December 2010. 
Exclusion criteria were bilateral or metastasized cancer and immediate breast 
reconstruction. Of the 1,536 eligible patients, 1,149 were asked to participate in the study. 
126 patients declined and 23 were withdrawn due to contraindication to the anaesthesia 
protocol, violation of the study protocol, or change in the type of surgery or for logistic 
reasons. The study protocol has earlier been described in detail.5 The age distribution of the 
patients was: ≤ 40 years (48), 41-60 years: (559 ), and 61-75 years: (393 ). No patient was 
taking strong opioids. Data on concomitant medications affecting the CYP3A/5 and CYP2D6 
pathways are shown is Suppl. Table 3. 
 
The Coordinating Ethics Committee (journal number 136/E0/2006) and the Ethics 
Committee of the Department of Surgery (148/E6/05) of the Hospital District of Helsinki and 
Uusimaa, and the Finnish Medicines Agency FIMEA had approved the study protocol. A 
written informed consent was obtained from each patient. After consent, demographic, 
medical and medication data were collected from all patients. The patients also filled the 
Beck Depression Inventory38 and the Spielberger State and Trait Anxiety Inventory39 
questionnaires. 
 
Before surgery, cold and heat pain sensitivities were assessed. In the cold pain sensitivity 
test, the patient immersed her hand into 40 l of cold (2-4 °C) water (Julabo USA Inc, 
Allenton, PA). Pain intensity was recorded every 15 seconds using NRS 0-10, zero 
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representing “no pain” and 10 “worst pain imaginable”. The patients were advised to 
withdraw the hand from the water at any time when the pain felt intolerable. The maximum 
time was set to 90 seconds. The time the patients kept the hand in the water was recorded. 
Heat pain was assessed with a thermode (16 mm x 16 mm) placed on the volar side of the 
forearm contralateral to surgery. The thermode (TSA-II, NeuroSensory Analyzee; Medoc Ltd, 
Ramat Yishai, Israel) was first heated to 43°C (control), and then to 48°C for 5 seconds. The 
patients were asked to assess the intensity of pain using NRS 0-10. Cold pain data were 
available from 900 patients only due to the unavailability of the test device in the beginning 
of the study. 
 
Surgery was personalised according to the patient’s wishes and the clinical characteristics of 
the tumor. Anesthesia was standardized. All patients were premedicated with peroral 
diazepam 2.5-15 mg and acetaminophen 1 g.  A venous blood sample was drawn for DNA 
analysis at the induction of anesthesia, which consisted of intravenous propofol and 
remifentanil. Before moving to the post-anesthesia care unit (PACU), all patients were given 
fentanyl (1 µg/kg intravenously, i.v.), ondansetron (4 mg i.v.), and dehydrobenzperidol (0.01 
mg/kg i.v.).  In the PACU, the patients were immediately asked to assess their pain intensity 
during rest and motion before the first oxycodone dose. Motion pain was tested by asking 
the patient to raise 90° her arm ipsilateral to the surgery. The research nurse asked the 
patients about rest and motion pain intensity every 5 min and administered them with 1-3 
mg i.v. oxycodone if they reported NRS >3. This was repeated until the patient indicated 
satisfactory analgesia, and the first blood sample for oxycodone and its metabolite 
determination was taken at this point. After this the pain scores were recorded every 15 
min until the patient required a new dose. At this time point the time from the previous 
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administration was recorded and the second blood sample was taken before the new dose 
was administered. After about 2.5 hours in the PACU, the patients were given a patient-
controlled analgesia (PCA) device and moved to the surgical ward. 
 
DNA extraction and genotyping 
DNA was extracted from peripheral blood using the Autopure LS automated DNA 
purification instrument (Gentra Systems Inc, Minneapolis, MN). All genotyping was done 
blindly to phenotype information. Patients were genotyped for 10 CYP2D6 SNVs and copy 
number variation using Taqman genotyping assays and a copy number assay targeting exon 
9.37 CYP2D6 metabolizer groups were inferred from the genotype data using the activity 
score method.40 CYP3A4 rs35599367 (*22) was genotyped with a commercially available kit 
(C_59013445_10) and the CYP3A5 rs776746 (*3) was assessed with a custom Taqman 
genotyping assay.41 Sequenom MassARRAY and iPLEX Gold Single Base Extension chemistry 
(Sequenom, San Diego, CA) were used to genotype OPRM1 rs1799971. Results were 
confirmed using duplicates and positive and negative control samples in each DNA plate.  
 
Measurement of oxycodone and its metabolites 
Plasma concentrations of oxycodone and three of its metabolites were quantified using an 
API 3000 liquid chromatography-tandem mass -spectrometry system (Sciex Division of MDS, 
Toronto, Ontario, Canada) as described previously, from 0.5 ml plasma samples (see Suppl. 
data 1).42 The method was validated according to the Food and Drug Administration 
guidelines.43 The lower limits of quantification for oxycodone and oxymorphone, and 
noroxycodone and noroxymorphone were 0.1 ng/mL and 0.25 ng/mL, respectively. Inter-






The data were analyzed using SPSS Statistics version 22 (IBM, New York, USA). Oxycodone 
and its metabolite concentrations below the limit of quantification were replaced with half 
of the quantification limit, except for those patients who did not need any oxycodone and 
were excluded from the respective analyses. Oxycodone and its metabolite concentrations 
were logarithmically transformed before statistical analysis. Possible effects of the variables 
affecting plasma oxycodone concentrations were investigated using a stepwise, forward 
linear regression analysis.  The tested variables included age, height, weight, lean body 
weight, body mass index (BMI), smoking status, preoperative anxiety, preoperative chronic 
pain condition, preoperative pain in the breast, OPRM1, CYP2D6 and CYP3A4 genotypes, 
surgery type (mastectomy/breast conserving and sentinel node biopsy/axillary clearance), 
preoperative cold and heat pain sensitivities, cold pain tolerance and postoperative rest and 
motion pain intensities. Statistical significance level was set at P < 0.05 for entry into the 
model and > 0.10 for removal. Possible effects of CYP2D6 genotypes on oxycodone 
metabolite concentrations were investigated with one-way analysis of variance as were the 
differences between postoperative pain intensity groups. The results are expressed as 
geometric means with geometric coefficients of variation or relative effects with 95% 
confidence intervals. Possible correlations of oxycodone and its metabolite concentrations 
between the two studied time points were investigated with the Pearson correlation 
coefficient. The differences between the 47 patients, who did not require any oxycodone, 
and the rest of the patients were investigated using independent sample T test for the 
continuous variables, Fisher’s exact test for the surgery type and Pearson’s chi-square for 
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OPRM1 genotype. Same statistical tests were also used to determine differences between 
the 539 patients who required additional oxycodone in the PACU after first satisfactory 







WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? 
Parenteral oxycodone is increasingly used for postoperative analgesia.  Individual analgesic 
doses of oxycodone vary significantly. 
 
WHAT QUESTION DID THIS STUDY ADDRESS? 
We examined individual analgesic plasma oxycodone concentrations and factors affecting 
them in 1,000 women after breast cancer surgery.   
 
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE 
The analgesic oxycodone concentrations varied more than 100-fold. Postoperative pain 
intensity and type of axillary surgery markedly affected the oxycodone concentration 
required for satisfactory analgesia. Patients with the highest motion pain intensity (scores 7-
10/10) need nearly three times higher plasma concentrations of oxycodone than patients 
with low (0-3) scores. Preoperatively assessed anxiety, heat or cold pain scores, or CYP3A, 
CYP2D6 or OPRM1 genotypes were not independently associated with the analgesic plasma 
oxycodone concentrations. 
 
HOW THIS MIGHT CHANGE CLINICAL PHARMACOLOGY AND THERAPEUTICS 
Postoperative motion pain intensity strongly predicts the oxycodone plasma concentration 
the patient will need for satisfactory analgesia. This information can be valuable for 
individualized postoperative pain relief and for the future design of pharmacogenetic 
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Table 1. Factors affecting the plasma oxycodone concentration at the time point when the patient 
reported satisfactory analgesia for the 1st time 
   
95% Confidence interval 
  
Variable B Lower Upper p 
Motion pain when the patient 
received the 1st oxycodone 
dose (per 1 point on a scale 
from 0 to 10) 
21.7 % 17.5 % 26.1 % <0.001 
Axillary clearance (vs. SNB) 23.4 % 12.1 % 36.0 % <0.001 




















































Pain at rest when the patient received the 

























 Results were obtained using forward type linear regression. Excluded variables are phenotypes 
tested but determined insignificant. 
R square for the model is 0.169 
R Square = coefficient of determination, Beta = standardized coefficients for model, B = Increase in 
oxycodone concentration needed for satisfactory analgesia, SNB = Sentinel Node Biopsy, STAI = 
Spielberger State Anxiety Inventory, BMI = Body Mass Index, NRS = Numerical Rating Scale (0-10) 






Table 2. Types of surgery and analgesic oxycodone doses and concentrations by pain intensity score 
groups 
 
 NRS 0-3 (n=59) NRS 4-6 (n=699) NRS 7-10 (n=170) 
Breast conserving surgery / 
Mastectomy (%) 35 / 24 (59 / 42) 452/247 (65 / 35) 91/79 (54 / 46) 
Sentinel node biopsy / Axillary 
clearance (%) 38 / 21 (64/ 36) 410/289 (59 / 41) 73/97 (43 / 57) 
Total amount of oxycodone needed 




    Geometric mean (CV%) 0.07 (73) 0.10 (62) 0.18 (48) 
  Range 0.01 - 0.3 0.02 - 0.6 0.03 -0.6 
Plasma concentration at the 1st state of 
satisfactory analgesia (ng/ml)       
 Oxycodone 
    
 
    Geometric mean (CV%) 17.8 (76) 31.6 (66) 50.7 (48) 
 
 Range <2.1 - 95.4 <0.1 - 311 9.6 - 130 
  Noroxycodone           
 
 Geometric mean (CV%) 0.8 (129) 1.3 (109) 3.3 (76) 
    Range <0.3 - 8.4 <0.3 -16.5 <0.3 - 20 
 Oxymorphone 
    
 
    Geometric mean (CV%) 0.1 (97) 0.1 (108) 0.2 (89) 
 
 Range <0.1 - 0.5 <0.1 - 1.1 <0.1 - 1.2 
  Noroxymorphone           
 
 Geometric mean (CV%) 0.2 (124) 0.2 (144) 0.5 (127) 
    Range <0.3 - 1.8 <0.3 - 5.2 <0.3 - 7.6 
Plasma concentration when the patient 
needed a new dose (ng/ml) 
  
 
  Oxycodone           
 
 Geometric mean (CV%) 11.0 (66) 20.9 (69) 31.5 (53) 
    Range 0.8 - 38.2 1.1 - 191 12.7 - 115.9 
 Noroxycodone 
    
 
    Geometric mean (CV%) 2.1 (90) 3.5 (69) 5.6 (62) 
 
 Range 0.5 - 12.6 0.2 - 17.1 0.5 - 19.3 
  Oxymorphone           
 
 Geometric mean (CV%) 0.1 (87) 0.1 (86) 0.2 (80) 
    Range <0.1 - 0.5 <0.1 - 1.4 <0.1 - 1.5 
 Noroxymorphone 
    
 
    Geometric mean (CV%) 0.4 (93) 0.6 (90) 1.0 (79) 
  Range <0.3 - 2.7 <0.3 - 6.6 <0.3 - 6.7 
 
Type of surgery, total amount of oxycodone needed and the oxycodone and metabolite 
concentrations at the 1st state of satisfactory analgesia in the patients who are divided into three 
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groups based on the intensity of motion pain after surgery before the first dose of oxycodone was 
administered. Continuous variables are given as geometric means and ranges. Categorical variables 
are given as number of patients and percentages. NRS numerical rating scale.  
CV% =coefficient of variation 
 
 
Table 3. Postoperative oxycodone doses and concentrations by CYP2D6 genotype 
  PM IM EM UM p 
Total amount of oxycodone needed 
by the 1st state of satisfactory 
analgesia (mg/kg) 
     
 Geometric mean (CV%) 0.09 (73) 0.12 (51) 0.11 (66) 0.12 (53) 0.323 
Duration of the analgesic effect 
(min) 
    
 
 
Geometric mean (CV%) 85.4 (118) 130.0 (86) 67.3 (121) 62.3 (121) 0.414 
Concentration at the 1st state of 
satisfactory analgesia (ng/ml) PM (n=23) IM (n=16) EM (n=799) UM (n=80) 
 
               Oxycodone      
 Geometric mean (CV%) 28.9 (73) 38.8 (48) 33.0 (67) 40.1 (53) 0.374 
 Range 5.7 - 130 14.1 - 88.1 <0.1 - 311 10.6 - 128  
              Noroxycodone      
 Geometric mean (CV%) 1.0 (112) 2.0 (86) 1.3 (107) 1.8 (92) 0.962 
 Range <0.1 - 8.7 <0.1 - 11.1 <0.1 - 20 0.1 - 13.4  
              Oxymorphone      
 Geometric mean (CV%) 0.05 (58) 0.06 (68) 0.11 (112) 0.17 (92) <0.001 
 Range <0.1 - 0.21 <0.1 - 0.22 <0.1 - 1.7 <0.1 - 1.1  
Noroxymorphone      
 Geometric mean (CV%) 0.05 (103) 0.07 (107) 0.17 (168) 0.26 (137) 0.003 
 Range <0.1 - 0.38 <0.1 - 0.38 <0.1 - 7.6 <0.1 - 5.2  
Concentration when the patient 
needed a new dose (ng/ml) PM (n=17) IM (n=4) EM (n=448) UM (n=52) 
 
               Oxycodone      
 Geometric mean (CV%) 17.6 (84) 23.8 (57) 21.6 (70) 24.5 (60) 0.629 
 Range 6.3 - 73.3 14.5 - 47.9 0.77 - 191.0 7.78 - 67.3  
              Noroxycodone      
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 Geometric mean (CV%) 3.2 (87) 6.3 (64) 3.7 (73) 3.7 (66) 0.879 
 Range 0.43 - 12.6 3.52 – 13.8 0.17 -19.3 0.57 - 14.2  
              Oxymorphone      
 Geometric mean (CV%) 0.06 (56) 0.09 (36) 0.14 (88) 0.22 (75) <0.001 
 Range <0.1 - 0.18 <0.1 - 0.13 <0.1 - 1.46 <0.1 - 0.97  
Noroxymorphone      
 Geometric mean (CV%) 0.06 (68) 0.27 (109) 0.62 (92) 1.02 (81) <0.001 
 Range <0.1 - 0.23 <0.1 – 1.2 <0.1 - 6.7 <0.1 - 5.1  
 
CV% = coefficient of variation 





















Figure 2. Correlations between plasma concentrations of oxycodone and its three main 
metabolites at the two time points: when the patient indicated satisfactory analgesia for the 
first time (1st state of satisfactory analgesia) and when the patient needed a new dose of 
oxycodone. The patients are divided into three groups based on the intensity of motion pain 
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after surgery before the first dose of oxycodone was administered. The geometric mean of 




Figure 3. Correlation between oxycodone doses (mg/kg) and plasma concentrations (ng/ml) 





Figure 4. The arithmetric means (SD) of analgesic oxycodone plasma concentrations by 
postoperative motion pain intensity score groups. NRS = Numerical Rating Scale (0-10).  
 
 
 
 
 
 
 
